Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $25.4 million.

  • Beta Bionics' Total Current Liabilities changed N/A to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year change of. This contributed to the annual value of $21.1 million for FY2024, which is 9941.54% up from last year.
  • According to the latest figures from Q3 2025, Beta Bionics' Total Current Liabilities is $25.4 million.
  • Beta Bionics' Total Current Liabilities' 5-year high stood at $25.4 million during Q3 2025, with a 5-year trough of $10.6 million in Q4 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $19.5 million (2025), whereas its average is $18.6 million.
  • The largest annual percentage gain for Beta Bionics' Total Current Liabilities in the last 5 years was 9941.54% (2024), contrasted with its biggest fall of 9941.54% (2024).
  • Beta Bionics' Total Current Liabilities (Quarter) stood at $10.6 million in 2023, then skyrocketed by 99.42% to $21.1 million in 2024, then rose by 20.05% to $25.4 million in 2025.
  • Its Total Current Liabilities stands at $25.4 million for Q3 2025, versus $19.5 million for Q2 2025 and $16.5 million for Q1 2025.